Data / Form D filings / ASURAGEN INC
ASURAGEN INC: Form D filings
ASURAGEN INC, a biotechnology company in Austin, TX, filed 2 Form D notices with the SEC between 2011 and 2013. The latest, on March 20, 2013, reports $7.5 million sold of a $15 million offering to 15 investors.
Find out what ASURAGEN INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2150 Woodward Street, SUITE 100, Austin, TX, 78744
- Phone
- (512) 681-5200
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1358480
The full lists. Form D filings in Texas: 4,800 rows, $128, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 20, 2013 | New notice | $15,000,000 | $7,500,000 | $7,500,000 | 15 | Mar 7, 2013 | sec.gov |
| Aug 11, 2011 | New notice | $10,000,000 | $5,000,000 | $5,000,000 | 1 | Jul 29, 2011 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Lynne J Hohlfeld | Executive Officer | |
| Ana J Ward | Executive Officer | |
| Carol J Berry | Executive Officer | |
| Matthew M Winkler | Executive Officer, Director | |
| David J Sargent | Director | |
| David J Rubin | Director | |
| Evan S Melrose | Director | |
| John E Mooney | Director | |
| Rolland M Carlson | Executive Officer, Director | |
| Robert J Dominici | Director | |
| Lyle E Arnold | Director | |
| Christopher D Earl | Director |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Mar 18, 2013 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ASURAGEN INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.